Short Sellers Run for Cover From Cybersecurity Stocks
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected cybersecurity stocks decreased.
All Work
Chris Lange
2018 Bull/Bear Outlook for FAANG Stocks
Some of the biggest winners in 2017 were the FAANG stocks, which have been a favorite of many investors and a staple for many portfolios. The question is where these big names go from…
Wednesday’s Biggest Winners and Losers in the S&P 500
Wednesday was a down day for the U.S. markets. The markets initially opened down, but over the course of the day they slowly moved back towards even. Earnings season just around the corner, and…
6 Blue Chips Getting Big Analyst Upgrades and Price Hikes
With 2018 off to a roaring start, analysts seem to be taking a hint and raising their target prices on their favorite blue chip stocks.
Domino’s Pizza CEO to Step Down in July
Domino’s Pizza shares took a step back on Wednesday after it was announced that the company’s long-standing CEO would be leaving the company.
Coca-Cola Restages Entire Diet Coke Brand
Early on Wednesday, Coca-Cola made a huge announcement, that it would be launching a full brand restage for Diet Coke.
Signet Goes Soft on 2018 Guidance
Signet Jewelers has joined the list of retailers that ultimately disappointed investors during this holiday season.
What to Expect From Facebook in 2018
Analysts are calling for Facebook to return less than 20% to investors in 2018, which might not seem like much compared to its performance in 2017.
Tuesday’s Biggest Winners and Losers in the S&P 500
Tuesday was another positive day for the markets, with all three of the major exchanges hitting all-time highs yet again. With earnings season just around the corner, we will finally get to see if…
Hulu Growth Threatens Amazon and Netflix
Netflix has long been the top dog of online streaming services, but as more companies are starting their own streaming services, Netflix could be losing out on some key subscribers.
Urban Outfitters Holiday Sales Not Enough for Investors
Urban Outfitters appears to be one of the retailers that faced a tough holiday season. Along with the likes of Macy’s, Nordstrom and Sears, Urban Outfitters just didn’t make the cut and investors inevitably…
Can Target Guidance Live Up to Expectations in 2018?
Target has posted updated guidance, and it seems to be one of the retailers that might be able to survive the Amazon storm.
Even More Investors Are Leveraging in to Bitcoin
Cryptocurrencies have taken Wall Street by storm, promising incredible returns in a relatively short time. Retail investors have been piling into these cryptocurrencies, to the point of leveraging their own finances to get more…
Nine Energy Announces Potential Pricing for IPO
Nine Energy Service expects to price its 7 million shares in the range that results in an initial public offering valued up to around $185 million.
JPMorgan, Wells Fargo and Other Earnings to Watch for This Week
The big banks generally kick off earnings season, and this week is no exception. While there are a couple of smaller stocks reporting this week, the big names are the banks, with even more…
Monday’s Biggest Winners and Losers in the S&P 500
Although Monday was a relatively mixed day for the markets, all three of the major exchanges hit all-time highs yet again. This is only the fifth trading day of the New Year and markets…
What Analysts Are Saying About Snap’s App Redesign
Snap was under fire in Monday’s session after one key brokerage firm crushed any expectations about the company’s recently announced app redesign.
Dave & Buster’s Isn’t Playing Around With Updated Guidance
Dave & Buster’s saw its shares get shredded in Monday’s session after the company provided an update on its fiscal full-year guidance.
Why Alder Biopharma Is Winning Big on Monday
Alder Biopharmaceuticals saw its shares make a solid gain on Monday amid a blizzard of updates from the company.
Axovant Crumbles Following Alzheimer’s Study Update
Axovant Sciences watched its shares practically get halved in Monday’s session after the firm provided an update from a few of its midstage clinical trials.